Is this your company? Get featured or correct your listing →
Recent changes
- Jun 26, 2026Jun 26, 2026Akari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the Clinic Pulse story
- May 20, 2026May 20, 2026Raised $1.8M SEC EDGAR Form D
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2026 | funding round | $1.8M | — | SEC EDGAR Form D |
Latest Pulse
- Jun 26, 2026TEN Holdings Prices a $7.5M Offering via S-1MEF as Micro-Cap Issuance StirsTEN Holdings (Nasdaq: XHLD), the parent of event production and broadcasting firm Ten Events, filed an S-1MEF with the SEC and priced a $7.5 million offering of 7.5 million shares at $1.00 each, with WestPark Capital as sole placement agent. The deal is a small but telling sign that capital-markets activity is reaching well down the cap-size spectrum, not just the marquee AI and biotech names.→
- Jun 26, 2026Akari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the ClinicOncology biotech Akari Therapeutics (Nasdaq: AKTX) filed a Form S-1/A with the SEC to register capital as it advances AKTX-101, a TROP2-targeting antibody-drug conjugate built on its proprietary PH1 payload platform. The filing adds another clinical-stage cancer name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.→
Coverage Timeline
newest firstAll Coverage
Related Companies
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.